Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience With   Potential for Improved Efficacy? Elie S. Al Kazzi, MD, MPH…

Risankizumab Is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC  Treatment Paradigm Rahul…

Risankizumab Is Superior to Ustekinumab for Induction and Maintenance of Crohn’s Disease: The SEQUENCE Trial Sara Ghoneim, MD1 and Bharati…

Long-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Long-Term Maintenance Study Rahul Dalal, MD,…

PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment? Bharati Kochar, MD, MS  Assistant Professor of Medicine, Division of…

Ustekinumab and Vedolizumab Demonstrate Safety During Pregnancy-Updates From the PIANO Registry Rahul Dalal, MD, MPH Instructor, Division of Gastroenterology, Hepatology,…

Mirikizumab Is Effective for Induction and Maintenance of Ulcerative Colitis Rahul Dalal, MD, MPH Instructor, Division of Gastroenterology, Hepatology, and…

Is Early Ileo-cecal Resection for Crohn’s Disease an Appropriate Primary Treatment?  Bharati Kochar, MD, MS   Assistant Professor of Medicine,…

Editor-in-Chief Dr Philip Schoenfeld looks at a Phase 3 trial published in Lancet of 463 patients with IBS treated with tri-cyclic antidepressant and the effect on a patient’s IBS-Symptom Severity Score.

Multiple treatments for ulcerative colitis are now available. We look at a study published detailing a multi-center, double-blind, placebo-controlled RCT on etrasimod.